Home » Inefficacy Kills Late-Stage Trial of Revlimid in Prostate Cancer
Inefficacy Kills Late-Stage Trial of Revlimid in Prostate Cancer
Celgene is stopping a Phase III trial of blockbuster myeloma drug Revlimid to treat castrate-resistant prostate cancer after the formulation failed to show benefit over placebo.
Clinical Trials Advisor
Clinical Trials Advisor
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May